Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment S...

2023-05-03 00:22 3350

Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...

2023-05-03 00:07 2041

China Jo-Jo Drugstores Receives Hangzhou Municipal People's Government Quality Management Excellence Award

HANGZHOU, China, May 2, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that the Co...

2023-05-02 20:30 3330

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...

2023-05-02 17:30 3590

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged inCanada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for i...

2023-05-02 05:00 2306

I-MAB Filed 2022 Annual Report on Form 20-F

GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20...

2023-05-01 20:00 2162

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary ar...

2023-05-01 18:30 2861

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...

2023-05-01 08:58 2714

OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products

SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...

2023-04-29 23:20 4335

IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study

SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Br...

2023-04-28 17:00 1875

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...

2023-04-28 14:43 2964

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health ...

2023-04-28 09:00 3031

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...

2023-04-28 08:58 2148

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...

2023-04-28 00:29 3120

Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation

- Aims to guide patients with rare and gastrointestinal diseases to appropriate medical care 〜Ubie will build on its achievements in the early detection of HAE and expand its collaboration with Takeda Pharmaceuticals to benefit patients in broader disease areas〜 NEW YORK, April 27, 2023 /PRNews...

2023-04-27 23:00 1894

Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published

SEOUL, South Korea, April 27, 2023 /PRNewswire/ -- At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide (project name: YP-P10). ARVO is the world's largest ophthalmic society and held its annual meeting inNew Orleans...

2023-04-27 21:00 2088

Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published

Fosun Collaborates with Non-profit Organizations to Provide "Chinese Solutions" to Jointly Build a Malaria-free World

HONG KONG, April 27, 2023 /PRNewswire/ -- A song spreads throughout the world from the Premier League fields; a seminar explores how civilian orgnanizations can carry out charitable activities for long-term effect inAfrica; and a charity "relay race" starts at Guilin,China, where artesunate was d...

2023-04-27 19:36 3258

ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates

SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...

2023-04-27 17:44 1820

BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ -- BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a$5.0m AUD grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to fund wor...

2023-04-27 12:15 2300

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announ...

2023-04-27 08:30 2904

1 ... 109 110 111112113 114 115 ... 316